Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up
The impact of statin use on localized prostate cancer (PCa) remains controversial, especially for patients treated with radiation therapy. We assessed the impact of statin use on biochemical recurrence (BCR) in patients treated for PCa with different modalities of radiation therapy. We evaluated 355...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-07, Vol.14 (15), p.3606 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 15 |
| container_start_page | 3606 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Kaulanjan, Kevin Lavigne, Danny Saad, Fred Karakiewicz, Pierre I. Flammia, Rocco Simone Kluth, Luis Alex Mandel, Philipp Chun, Felix K. -H. Taussky, Daniel Hoeh, Benedikt |
| description | The impact of statin use on localized prostate cancer (PCa) remains controversial, especially for patients treated with radiation therapy. We assessed the impact of statin use on biochemical recurrence (BCR) in patients treated for PCa with different modalities of radiation therapy. We evaluated 3555 patients undergoing radiation therapy between January 2001 and January 2022. The impact of statin use on BCR was analyzed for three treatment groups: external beam radiotherapy (EBRT), low-dose-rate seed brachytherapy (LDR), and EBRT plus high-dose-rate brachytherapy (EBRT + HDR). Median follow-up was 52 months among 1208 patients treated with EBRT, 1679 patients treated with LDR, and 599 patients treated with EBRT + HDR. A total of 1544 (43%) patients were taking a statin at the time of treatment, and 497 (14%) patients were in the D’Amico high-risk group. Only intermediate-risk patients treated with LDR fared better with statin use in univariate analysis (p = 0.025). This association was not significant in multivariate analysis (HR 0.44, 95% CI 0.18–1.10, p = 0.06). Statin use was not associated with a reduced risk of BCR in patients treated with radiation therapy. In the era of precision medicine, further investigation is needed to assess the benefit of statins in well-defined patients. |
| doi_str_mv | 10.3390/cancers14153606 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9331711</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2700529596</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-ed0ccb3821b7b2acf7384b8d971c0c0b984430700bdf1c3c62c33f47278b90123</originalsourceid><addsrcrecordid>eNpdUUlLxTAQDqKoqGevAS9eqlnaLB4EebjBA0XfO4d0mj4rbVOTVtFfb1wQdS4zw3zfNxtC-5Qcca7JMdgeXIg0pwUXRKyhbUYky4TQ-fqveAvtxfhIknFOpZCbaIsXSjMlim20uu4GCyP2Nb4f7dj0eBkd9j2ee7Bt8-YqfBt8TCWHZ5_98M00gu9cxLYeU3pnqyYRE2Xx4IIdXk8St19lCxc6fOHb1r9ky2EXbdS2jW7v2--g5cX5YnaVzW8ur2dn8wy4VmPmKgJQcsVoKUtmoZZc5aWqtKRAgJRa5TknkpCyqilwEAw4r3PJpCo1oYzvoNMv3WEqO1eB68dgWzOEprPh1XjbmL-VvnkwK_9s9MdxKE0Ch98CwT9NLo6mayK4trW981M0TOiCKZXLIkEP_kEf_RT6tJ5hacSC6UKLhDr-QkG6Ywyu_hmGEvPxR_Pvj_wdWF6Qgw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2700529596</pqid></control><display><type>article</type><title>Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Kaulanjan, Kevin ; Lavigne, Danny ; Saad, Fred ; Karakiewicz, Pierre I. ; Flammia, Rocco Simone ; Kluth, Luis Alex ; Mandel, Philipp ; Chun, Felix K. -H. ; Taussky, Daniel ; Hoeh, Benedikt</creator><creatorcontrib>Kaulanjan, Kevin ; Lavigne, Danny ; Saad, Fred ; Karakiewicz, Pierre I. ; Flammia, Rocco Simone ; Kluth, Luis Alex ; Mandel, Philipp ; Chun, Felix K. -H. ; Taussky, Daniel ; Hoeh, Benedikt</creatorcontrib><description>The impact of statin use on localized prostate cancer (PCa) remains controversial, especially for patients treated with radiation therapy. We assessed the impact of statin use on biochemical recurrence (BCR) in patients treated for PCa with different modalities of radiation therapy. We evaluated 3555 patients undergoing radiation therapy between January 2001 and January 2022. The impact of statin use on BCR was analyzed for three treatment groups: external beam radiotherapy (EBRT), low-dose-rate seed brachytherapy (LDR), and EBRT plus high-dose-rate brachytherapy (EBRT + HDR). Median follow-up was 52 months among 1208 patients treated with EBRT, 1679 patients treated with LDR, and 599 patients treated with EBRT + HDR. A total of 1544 (43%) patients were taking a statin at the time of treatment, and 497 (14%) patients were in the D’Amico high-risk group. Only intermediate-risk patients treated with LDR fared better with statin use in univariate analysis (p = 0.025). This association was not significant in multivariate analysis (HR 0.44, 95% CI 0.18–1.10, p = 0.06). Statin use was not associated with a reduced risk of BCR in patients treated with radiation therapy. In the era of precision medicine, further investigation is needed to assess the benefit of statins in well-defined patients.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14153606</identifier><identifier>PMID: 35892865</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Androgens ; Antitumor agents ; Brachytherapy ; Cancer therapies ; Classification ; Multivariate analysis ; Patients ; Population ; Precision medicine ; Prostate cancer ; Radiation therapy ; Risk groups ; Statins</subject><ispartof>Cancers, 2022-07, Vol.14 (15), p.3606</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-ed0ccb3821b7b2acf7384b8d971c0c0b984430700bdf1c3c62c33f47278b90123</citedby><cites>FETCH-LOGICAL-c398t-ed0ccb3821b7b2acf7384b8d971c0c0b984430700bdf1c3c62c33f47278b90123</cites><orcidid>0000-0001-6152-6725 ; 0000-0002-4459-9196 ; 0000-0002-3129-0544 ; 0000-0003-2986-5617</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331711/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331711/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Kaulanjan, Kevin</creatorcontrib><creatorcontrib>Lavigne, Danny</creatorcontrib><creatorcontrib>Saad, Fred</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I.</creatorcontrib><creatorcontrib>Flammia, Rocco Simone</creatorcontrib><creatorcontrib>Kluth, Luis Alex</creatorcontrib><creatorcontrib>Mandel, Philipp</creatorcontrib><creatorcontrib>Chun, Felix K. -H.</creatorcontrib><creatorcontrib>Taussky, Daniel</creatorcontrib><creatorcontrib>Hoeh, Benedikt</creatorcontrib><title>Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up</title><title>Cancers</title><description>The impact of statin use on localized prostate cancer (PCa) remains controversial, especially for patients treated with radiation therapy. We assessed the impact of statin use on biochemical recurrence (BCR) in patients treated for PCa with different modalities of radiation therapy. We evaluated 3555 patients undergoing radiation therapy between January 2001 and January 2022. The impact of statin use on BCR was analyzed for three treatment groups: external beam radiotherapy (EBRT), low-dose-rate seed brachytherapy (LDR), and EBRT plus high-dose-rate brachytherapy (EBRT + HDR). Median follow-up was 52 months among 1208 patients treated with EBRT, 1679 patients treated with LDR, and 599 patients treated with EBRT + HDR. A total of 1544 (43%) patients were taking a statin at the time of treatment, and 497 (14%) patients were in the D’Amico high-risk group. Only intermediate-risk patients treated with LDR fared better with statin use in univariate analysis (p = 0.025). This association was not significant in multivariate analysis (HR 0.44, 95% CI 0.18–1.10, p = 0.06). Statin use was not associated with a reduced risk of BCR in patients treated with radiation therapy. In the era of precision medicine, further investigation is needed to assess the benefit of statins in well-defined patients.</description><subject>Androgens</subject><subject>Antitumor agents</subject><subject>Brachytherapy</subject><subject>Cancer therapies</subject><subject>Classification</subject><subject>Multivariate analysis</subject><subject>Patients</subject><subject>Population</subject><subject>Precision medicine</subject><subject>Prostate cancer</subject><subject>Radiation therapy</subject><subject>Risk groups</subject><subject>Statins</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdUUlLxTAQDqKoqGevAS9eqlnaLB4EebjBA0XfO4d0mj4rbVOTVtFfb1wQdS4zw3zfNxtC-5Qcca7JMdgeXIg0pwUXRKyhbUYky4TQ-fqveAvtxfhIknFOpZCbaIsXSjMlim20uu4GCyP2Nb4f7dj0eBkd9j2ee7Bt8-YqfBt8TCWHZ5_98M00gu9cxLYeU3pnqyYRE2Xx4IIdXk8St19lCxc6fOHb1r9ky2EXbdS2jW7v2--g5cX5YnaVzW8ur2dn8wy4VmPmKgJQcsVoKUtmoZZc5aWqtKRAgJRa5TknkpCyqilwEAw4r3PJpCo1oYzvoNMv3WEqO1eB68dgWzOEprPh1XjbmL-VvnkwK_9s9MdxKE0Ch98CwT9NLo6mayK4trW981M0TOiCKZXLIkEP_kEf_RT6tJ5hacSC6UKLhDr-QkG6Ywyu_hmGEvPxR_Pvj_wdWF6Qgw</recordid><startdate>20220724</startdate><enddate>20220724</enddate><creator>Kaulanjan, Kevin</creator><creator>Lavigne, Danny</creator><creator>Saad, Fred</creator><creator>Karakiewicz, Pierre I.</creator><creator>Flammia, Rocco Simone</creator><creator>Kluth, Luis Alex</creator><creator>Mandel, Philipp</creator><creator>Chun, Felix K. -H.</creator><creator>Taussky, Daniel</creator><creator>Hoeh, Benedikt</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6152-6725</orcidid><orcidid>https://orcid.org/0000-0002-4459-9196</orcidid><orcidid>https://orcid.org/0000-0002-3129-0544</orcidid><orcidid>https://orcid.org/0000-0003-2986-5617</orcidid></search><sort><creationdate>20220724</creationdate><title>Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up</title><author>Kaulanjan, Kevin ; Lavigne, Danny ; Saad, Fred ; Karakiewicz, Pierre I. ; Flammia, Rocco Simone ; Kluth, Luis Alex ; Mandel, Philipp ; Chun, Felix K. -H. ; Taussky, Daniel ; Hoeh, Benedikt</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-ed0ccb3821b7b2acf7384b8d971c0c0b984430700bdf1c3c62c33f47278b90123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Androgens</topic><topic>Antitumor agents</topic><topic>Brachytherapy</topic><topic>Cancer therapies</topic><topic>Classification</topic><topic>Multivariate analysis</topic><topic>Patients</topic><topic>Population</topic><topic>Precision medicine</topic><topic>Prostate cancer</topic><topic>Radiation therapy</topic><topic>Risk groups</topic><topic>Statins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaulanjan, Kevin</creatorcontrib><creatorcontrib>Lavigne, Danny</creatorcontrib><creatorcontrib>Saad, Fred</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I.</creatorcontrib><creatorcontrib>Flammia, Rocco Simone</creatorcontrib><creatorcontrib>Kluth, Luis Alex</creatorcontrib><creatorcontrib>Mandel, Philipp</creatorcontrib><creatorcontrib>Chun, Felix K. -H.</creatorcontrib><creatorcontrib>Taussky, Daniel</creatorcontrib><creatorcontrib>Hoeh, Benedikt</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaulanjan, Kevin</au><au>Lavigne, Danny</au><au>Saad, Fred</au><au>Karakiewicz, Pierre I.</au><au>Flammia, Rocco Simone</au><au>Kluth, Luis Alex</au><au>Mandel, Philipp</au><au>Chun, Felix K. -H.</au><au>Taussky, Daniel</au><au>Hoeh, Benedikt</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up</atitle><jtitle>Cancers</jtitle><date>2022-07-24</date><risdate>2022</risdate><volume>14</volume><issue>15</issue><spage>3606</spage><pages>3606-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The impact of statin use on localized prostate cancer (PCa) remains controversial, especially for patients treated with radiation therapy. We assessed the impact of statin use on biochemical recurrence (BCR) in patients treated for PCa with different modalities of radiation therapy. We evaluated 3555 patients undergoing radiation therapy between January 2001 and January 2022. The impact of statin use on BCR was analyzed for three treatment groups: external beam radiotherapy (EBRT), low-dose-rate seed brachytherapy (LDR), and EBRT plus high-dose-rate brachytherapy (EBRT + HDR). Median follow-up was 52 months among 1208 patients treated with EBRT, 1679 patients treated with LDR, and 599 patients treated with EBRT + HDR. A total of 1544 (43%) patients were taking a statin at the time of treatment, and 497 (14%) patients were in the D’Amico high-risk group. Only intermediate-risk patients treated with LDR fared better with statin use in univariate analysis (p = 0.025). This association was not significant in multivariate analysis (HR 0.44, 95% CI 0.18–1.10, p = 0.06). Statin use was not associated with a reduced risk of BCR in patients treated with radiation therapy. In the era of precision medicine, further investigation is needed to assess the benefit of statins in well-defined patients.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>35892865</pmid><doi>10.3390/cancers14153606</doi><orcidid>https://orcid.org/0000-0001-6152-6725</orcidid><orcidid>https://orcid.org/0000-0002-4459-9196</orcidid><orcidid>https://orcid.org/0000-0002-3129-0544</orcidid><orcidid>https://orcid.org/0000-0003-2986-5617</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-07, Vol.14 (15), p.3606 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9331711 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Androgens Antitumor agents Brachytherapy Cancer therapies Classification Multivariate analysis Patients Population Precision medicine Prostate cancer Radiation therapy Risk groups Statins |
| title | Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T01%3A58%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Statin%20Use%20on%20Localized%20Prostate%20Cancer%20Outcomes%20after%20Radiation%20Therapy:%20Long-Term%20Follow-Up&rft.jtitle=Cancers&rft.au=Kaulanjan,%20Kevin&rft.date=2022-07-24&rft.volume=14&rft.issue=15&rft.spage=3606&rft.pages=3606-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14153606&rft_dat=%3Cproquest_pubme%3E2700529596%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2700529596&rft_id=info:pmid/35892865&rfr_iscdi=true |